Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Full text

Free full text

Publication Types

Journal Article

Multicenter Study

Review

Research Support, Non-U.S. Gov't

Randomized Controlled Trial

Clinical Trial, Phase II

Clinical Trial, Phase I

Clinical Trial, Phase III

Case Reports

Publication Year

From

Quick links

Individual year

2024

2022

2021

2020

2017

2015

2014

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Brentuximab Vedotin""[mesh_terms]

10 Results

Searching titles within these results

Discovery and Development of Dolastatin 10-Derived Antibody Drug Conjugate Anticancer Drugs.

Sheo B Singh

Journal of natural products 2022;85(3):666-687

Full Text

Abstract

AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial.

Stephanie Sasse, Paul Jan Bröckelmann, Jesko Momotow, Annette Plütschow, Andreas Hüttmann, Nadezda Basara, Christian Koenecke, Sonja Martin, Martin Bentz, Christina Grosse-Thie, Sven Thorspecken, Maike de Wit, Carsten Kobe, Markus Dietlein, Bastian von Tresckow, Michael Fuchs, Peter Borchmann, Andreas Engert

Leukemia & lymphoma 2022;63(8):1871-1878

Full Text

Abstract

Case Report: Brentuximab Vedotin Associated Acute Pancreatitis in a Pediatric Hodgkin Lymphoma Patient: Case Report and Literature Review.

Ewelina Truszkowska, Marta Andrzejewska, Cyntia Szymańska, Agnieszka Wziątek, Katarzyna Derwich

Pathology oncology research : POR 2022;28():1610445

Free Full Text

Abstract

Characterization of the Primary Structure of Cysteine-Linked Antibody-Drug Conjugates Using Capillary Electrophoresis with Mass Spectrometry.

Josiane Saadé, Rabah Gahoual, Alain Beck, Emmanuelle Leize-Wagner, Yannis-Nicolas François

Methods in molecular biology (Clifton, N.J.) 2021;2078():263-272

Full Text

Abstract

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial.

Pratyush Giri, Vladan Vucinic, Alden Moccia, Andreas Zimmermann, Urban Novak, Stephan Mathas, Karolin Behringer, Wolfram Klapper, Maike de Wit, Judith Dierlamm, Hans-Joachim Beck, Sonja Martin, Helen Kaul, Michael Hallek, Hans-Theodor Eich, Andreas Viardot, Max S Topp, Mark Hertzberg, Stefanie Kreissl, Volker Diehl, Mathias Hänel, Christian Baues, Julia Meissner, Karolin Trautmann-Grill, Andrea Kerkhoff, Peter Borchmann, Carsten Kobe, Michael Fuchs, Richard Greil, Bernd Hertenstein, Sebastian Scholl, Josée M Zijlstra, Felix Keil, Andreas Rosenwald, Justin Ferdinandus, Andreas Hüttmann, Bastian von Tresckow, Markus Dietlein, Alexander Fosså, Roland Schroers, Gundolf Schneider, Valdete Schaub, Wolfram Jung, Benjamin Unger, Andreas Rank, Christian Meyer Zum Büschenfelde, Peter Kamper, Daniel Molin, Sven Borchmann, Athanasios Zomas

Lancet (London, England) 2024;404(10450):341-352

Free Full Text

Abstract

Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.

Catherine S Diefenbach, Fangxin Hong, Richard F Ambinder, Jonathon B Cohen, Michael J Robertson, Kevin A David, Ranjana H Advani, Timothy S Fenske, Stefan K Barta, Neil D Palmisiano, Jakub Svoboda, David S Morgan, Reem Karmali, Elad Sharon, Howard Streicher, Brad S Kahl, Stephen M Ansell

The Lancet. Haematology 2020;7(9):e660-e670

Free Full Text

Abstract

Site-specific antibody drug conjugates for cancer therapy.

Siler Panowski, Sunil Bhakta, Helga Raab, Paul Polakis, Jagath R Junutula

mAbs 2014;6(1):34-45

Free Full Text

Abstract

CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies.

Owen A O'Connor, Ajay K Gopal, Andre Goy, Tae H Han, Radhakrishnan Ramchandren, Robert Chen, Jeffrey V Matous, Maureen Cooper, Laurie E Grove, Stephen C Alley, Carmel M Lynch

Journal of clinical pharmacology 2014;53(8):866-77

Free Full Text

Abstract

Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.

Bertrand Coiffier, Massimo Federico, Dolores Caballero, Claire Dearden, Franck Morschhauser, Ulrich Jäger, Lorenz Trümper, Emanuele Zucca, Maria Gomes da Silva, Ruth Pettengell, Eckhart Weidmann, Francesco d'Amore, Hervé Tilly, Pier Luigi Zinzani

Cancer treatment reviews 2015;40(9):1080-8

Free Full Text

Abstract

Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.

Dennis A Eichenauer, Annette Plütschow, Stefanie Kreissl, Martin Sökler, Johannes C Hellmuth, Julia Meissner, Stephan Mathas, Max S Topp, Karolin Behringer, Wolfram Klapper, Georg Kuhnert, Markus Dietlein, Carsten Kobe, Michael Fuchs, Volker Diehl, Andreas Engert, Peter Borchmann

The Lancet. Oncology 2017;18(12):1680-1687

Full Text

Abstract

Results: 1 – 10 / 10

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Brentuximab Vedotin""[mesh_terms]

Discovery and Development of Dolastatin 10-Derived Antibody Drug Conjugate Anticancer Drugs.

AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial.

Case Report: Brentuximab Vedotin Associated Acute Pancreatitis in a Pediatric Hodgkin Lymphoma Patient: Case Report and Literature Review.

Characterization of the Primary Structure of Cysteine-Linked Antibody-Drug Conjugates Using Capillary Electrophoresis with Mass Spectrometry.

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial.

Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.

Site-specific antibody drug conjugates for cancer therapy.

CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies.

Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.

Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.

Results for
""Brentuximab Vedotin""[mesh_terms]